Table 2 Clinical trials with mRNA vaccines against infectious diseases

From: mRNA vaccines — a new era in vaccinology

Sponsoring institution

Vaccine type (route of administration)

Targets

Trial numbers (phase)

Status

Argos Therapeutics

DC EP with autologous viral Ag and CD40L mRNAs (i.d.)

HIV-1

• NCT00672191 (II)

• NCT01069809 (II)

• NCT02042248 (I)

• Completed105

• Completed; results NA

• Completed; results NA

CureVac AG

RNActive viral Ag mRNA (i.m., i.d.)

Rabies virus

NCT02241135 (I)

Active56,91

Erasmus Medical Center

DC loaded with viral Ag mRNA with TriMix (i.nod.)

HIV-1

NCT02888756 (II)

Recruiting

Fundació Clínic per la Recerca Biomèdica

Viral Ag mRNA with TriMix (NA)

HIV-1

NCT02413645 (I)

Active

Massachusetts General Hospital

DC loaded with viral Ag mRNA (i.d.)

HIV-1

NCT00833781 (II)

Completed104

McGill University Health Centre

DC EP with autologous viral Ag and CD40L mRNAs (i.d.)

HIV-1

NCT00381212 (I/II)

Completed102

Moderna Therapeutics

Nucleoside-modified viral Ag mRNA (i.m.)

Zika virus

NCT03014089 (I/II)

Recruiting85

Influenza virus

NCT03076385 (I)

Ongoing22

  1. The table summarizes the clinical trials registered at ClinicalTrials.gov as of 5 May 2017. Ag, antigen; CD40L, CD40 ligand; DC, dendritic cell; EP, electroporated; i.d., intradermal; i.m., intramuscular; i.nod., intranodal; NA, not available.
PowerPoint slide
Back to article page